Hoehn, Daniela

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., et al. (2024) · The Lancet Haematology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 171

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P. J., et al. (2025) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 15

EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL

Vose, J., Vitolo, U., Lugtenburg, P., Chamuleau, M. E. D., Linton, K. M., Thieblemont, C., Sonnevi, K., Jurczak, W., Olszewski, A. J., Awan, F. T., et al. (2024) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 10